GENTIAN DIAGNOSTICS Financials Gentian Diagnostics
Equities
GENT
NO0010748866
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.8 NOK | +4.39% |
|
+2.88% | +3.13% |
| Apr. 30 | Gentian Diagnostics ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 30 | Transcript : Gentian Diagnostics ASA, Q1 2024 Earnings Call, Apr 30, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 961.1 | 839.9 | 1,110 | 632.3 | 640 | 660.1 | - | - |
| Enterprise Value (EV) 1 | 961.1 | 683.6 | 1,014 | 566 | 565.4 | 597.1 | 595.1 | 660.1 |
| P/E ratio | - | -48.2 x | -44.8 x | -26.8 x | -60.1 x | 86.1 x | 48.7 x | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 17.4 x | 10.6 x | 11 x | 5.65 x | 4.5 x | 3.78 x | 2.92 x | 2.51 x |
| EV / Revenue | 17.4 x | 8.66 x | 10 x | 5.06 x | 3.97 x | 3.42 x | 2.63 x | 2.51 x |
| EV / EBITDA | - | -61 x | -133 x | -43.6 x | 173 x | 40.6 x | 24.7 x | 64.8 x |
| EV / FCF | - | -55 x | -24.7 x | -18.7 x | 53.4 x | -119 x | 66.1 x | - |
| FCF Yield | - | -1.82% | -4.05% | -5.36% | 1.87% | -0.84% | 1.51% | - |
| Price to Book | - | - | - | 4.1 x | 4.36 x | 4.26 x | 3.92 x | - |
| Nbr of stocks (in thousands) | 15,403 | 15,412 | 15,422 | 15,422 | 15,422 | 15,422 | - | - |
| Reference price 2 | 62.40 | 54.50 | 72.00 | 41.00 | 41.50 | 42.80 | 42.80 | 42.80 |
| Announcement Date | 2/14/20 | 2/11/21 | 2/17/22 | 2/16/23 | 2/9/24 | - | - | - |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 55.38 | 78.9 | 101.3 | 111.9 | 142.3 | 174.5 | 225.9 | 262.9 |
| EBITDA 1 | - | -11.2 | -7.6 | -12.99 | 3.273 | 14.7 | 24.14 | 10.19 |
| EBIT 1 | - | -17.8 | -14.91 | -23.24 | -12.76 | 3.633 | 10.39 | -6.902 |
| Operating Margin | - | -22.56% | -14.72% | -20.76% | -8.97% | 2.08% | 4.6% | -2.63% |
| Earnings before Tax (EBT) 1 | - | -17.47 | -24.76 | -23.62 | -10.36 | 7.671 | 13.55 | -3.764 |
| Net income 1 | -39.86 | -17.47 | -24.76 | -23.62 | -10.36 | 7.671 | 13.55 | -3.764 |
| Net margin | -71.96% | -22.14% | -24.45% | -21.1% | -7.28% | 4.4% | 6% | -1.43% |
| EPS 2 | - | -1.130 | -1.606 | -1.530 | -0.6900 | 0.4974 | 0.8783 | - |
| Free Cash Flow 1 | - | -12.42 | -41.06 | -30.33 | 10.58 | -5 | 9 | - |
| FCF margin | - | -15.74% | -40.55% | -27.1% | 7.43% | -2.87% | 3.98% | - |
| FCF Conversion (EBITDA) | - | - | - | - | 323.28% | - | 37.29% | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | 66.44% | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/14/20 | 2/11/21 | 2/17/22 | 2/16/23 | 2/9/24 | - | - | - |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Net sales 1 | 26.19 | 23.09 | 32.88 | 25.09 | 30.87 | 33.6 |
| EBITDA 1 | -0.6 | -4.184 | -1.241 | -6.062 | -1.504 | -0.516 |
| EBIT 1 | -1.583 | -6.246 | -3.98 | -8.737 | -4.271 | -2.875 |
| Operating Margin | -6.04% | -27.05% | -12.11% | -34.83% | -13.84% | -8.56% |
| Earnings before Tax (EBT) 1 | -9.545 | -6.625 | -2.99 | -9.378 | -4.625 | -0.657 |
| Net income 1 | -9.545 | -6.625 | -2.99 | -9.378 | -4.625 | -0.657 |
| Net margin | -36.44% | -28.69% | -9.09% | -37.38% | -14.98% | -1.96% |
| EPS | -0.6190 | -0.4300 | -0.1900 | -0.6100 | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/17/22 | 4/28/22 | 8/25/22 | 10/27/22 | 2/16/23 | 5/5/23 |
1NOK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 156 | 96.4 | 66.3 | 74.6 | 63 | 65 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -12.4 | -41.1 | -30.3 | 10.6 | -5 | 9 | - |
| ROE (net income / shareholders' equity) | - | - | -13.4% | -14.4% | -2.59% | 5.1% | 8.4% | - |
| ROA (Net income/ Total Assets) | - | -7.55% | -11.1% | -11.8% | -2.11% | 4.2% | 7% | - |
| Assets 1 | - | 231.2 | 224 | 199.8 | 491.2 | 182.6 | 193.5 | - |
| Book Value Per Share 2 | - | - | - | 10.00 | 9.510 | 10.00 | 10.90 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | 2.73 | 1.97 | 14.8 | 4.88 | 10 | 9 | - |
| Capex / Sales | - | 3.46% | 1.95% | 13.21% | 3.43% | 5.73% | 3.98% | - |
| Announcement Date | 2/14/20 | 2/11/21 | 2/17/22 | 2/16/23 | 2/9/24 | - | - | - |
1NOK in Million2NOK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
42.8
NOK
Average target price
57
NOK
Spread / Average Target
+33.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.13% | 62.78M | |
| -3.43% | 12.45B | |
| -3.17% | 8.22B | |
| +6.11% | 5.72B | |
| +31.98% | 5.67B | |
| -10.03% | 4.11B | |
| -59.94% | 2.68B | |
| +11.23% | 2.68B | |
| -5.14% | 2.37B | |
| +18.91% | 2.06B |
- Stock Market
- Equities
- GENT Stock
- Financials Gentian Diagnostics
